Log in

NASDAQ:NRCNational Research Stock Price, Forecast & News

+2.29 (+4.21 %)
(As of 06/1/2020 04:00 PM ET)
Today's Range
Now: $56.72
50-Day Range
MA: $52.67
52-Week Range
Now: $56.72
Volume65,600 shs
Average Volume37,339 shs
Market Capitalization$1.43 billion
P/E Ratio40.51
Dividend Yield1.48%
National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company's portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company's clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars

Industry, Sector and Symbol

Industry Commercial physical research
SectorBusiness Services
Current SymbolNASDAQ:NRC



Sales & Book Value

Annual Sales$127.98 million
Cash Flow$1.52 per share
Book Value$1.32 per share


Net Income$32.41 million


Market Cap$1.43 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive NRC News and Ratings via Email

Sign-up to receive the latest news and ratings for NRC and its competitors with MarketBeat's FREE daily newsletter.

National Research (NASDAQ:NRC) Frequently Asked Questions

How has National Research's stock been impacted by COVID-19 (Coronavirus)?

National Research's stock was trading at $52.18 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NRC stock has increased by 8.7% and is now trading at $56.72. View which stocks have been most impacted by Coronavirus.

When is National Research's next earnings date?

National Research is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for National Research.

How were National Research's earnings last quarter?

National Research Co. (NASDAQ:NRC) released its quarterly earnings data on Tuesday, May, 5th. The company reported $0.46 earnings per share for the quarter. The company earned $33.86 million during the quarter. National Research had a net margin of 27.59% and a return on equity of 114.97%. View National Research's earnings history.

How often does National Research pay dividends? What is the dividend yield for National Research?

National Research declared a quarterly dividend on Wednesday, March 11th. Investors of record on Tuesday, March 31st will be given a dividend of $0.21 per share on Wednesday, April 15th. This represents a $0.84 annualized dividend and a yield of 1.48%. The ex-dividend date of this dividend is Monday, March 30th. View National Research's dividend history.

Has National Research been receiving favorable news coverage?

Press coverage about NRC stock has been trending very positive on Tuesday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. National Research earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutNational Research.

Are investors shorting National Research?

National Research saw a increase in short interest in May. As of May 15th, there was short interest totaling 149,600 shares, an increase of 35.4% from the April 30th total of 110,500 shares. Based on an average daily trading volume, of 41,700 shares, the short-interest ratio is currently 3.6 days. Approximately 1.1% of the shares of the stock are sold short. View National Research's Current Options Chain.

Who are some of National Research's key competitors?

What other stocks do shareholders of National Research own?

Based on aggregate information from My MarketBeat watchlists, some companies that other National Research investors own include Altria Group (MO), AbbVie (ABBV), Dominion Energy (D), Gilead Sciences (GILD), Verizon Communications (VZ), Exxon Mobil (XOM), Enbridge (ENB), Enterprise Products Partners (EPD), Harley-Davidson (HOG) and IBM (IBM).

Who are National Research's key executives?

National Research's management team includes the following people:
  • Steven D. Jackson, President (Age 41)
  • Michael D. Hays, Chief Executive Officer, Director (Age 62)
  • Kevin R. Karas, Chief Financial Officer, Senior Vice President - Finance, Treasurer, Secretary (Age 59)
  • John N. Nunnelly, Lead Independent Director (Age 64)
  • Donald M. Berwick M.D., Independent Director (Age 70)
  • JoAnn M. Martin, Independent Director (Age 62)
  • Barbara J Mowry, Independent Director (Age 69)

What is National Research's stock symbol?

National Research trades on the NASDAQ under the ticker symbol "NRC."

Who are National Research's major shareholders?

National Research's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.45%), Conestoga Capital Advisors LLC (2.47%), State Street Corp (1.03%), Geode Capital Management LLC (0.77%), Comerica Bank (0.47%) and Bank of New York Mellon Corp (0.42%). Company insiders that own National Research stock include Amandla Mk Trust, Barbara Mowry, Donald M Berwick, K/I/E Trust Under Agreement 10, K/I/E/Trust Under Agreement 3/, Kevin R Karas and Steven D Jackson. View institutional ownership trends for National Research.

Which institutional investors are selling National Research stock?

NRC stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Invesco Ltd., First Trust Advisors LP, Advisory Research Inc., First Quadrant L P CA, Bank of New York Mellon Corp, UBS Group AG, and Parametric Portfolio Associates LLC. Company insiders that have sold National Research company stock in the last year include Amandla Mk Trust, Barbara Mowry, Donald M Berwick, Kevin R Karas, and Steven D Jackson. View insider buying and selling activity for National Research.

Which institutional investors are buying National Research stock?

NRC stock was purchased by a variety of institutional investors in the last quarter, including Comerica Bank, JPMorgan Chase & Co., AQR Capital Management LLC, BlackRock Inc., State Street Corp, Dupont Capital Management Corp, Geode Capital Management LLC, and State Board of Administration of Florida Retirement System. View insider buying and selling activity for National Research.

How do I buy shares of National Research?

Shares of NRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is National Research's stock price today?

One share of NRC stock can currently be purchased for approximately $56.72.

How big of a company is National Research?

National Research has a market capitalization of $1.43 billion and generates $127.98 million in revenue each year.

What is National Research's official website?

The official website for National Research is www.nrchealth.com.

How can I contact National Research?

National Research's mailing address is 1245 Q STREET, LINCOLN NE, 68508. The company can be reached via phone at 402-475-2525.

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.